Last checked at 23 Nov 2018 07:00
23 November 2018
OXFORD BIODYNAMICS PLC
("OBD" or the "Company" or the "Group")
Notice of results for the year ended 30 September 2018
Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, expects to announce its full year results for the year ended 30 September 2018 on Tuesday 11 December 2018.
For further details please contact:
Oxford BioDynamics Plc. | +44 (0)1865 518910 | |
Christian Hoyer Millar, CEO | ||
Paul Stockdale, CFO | ||
Shore Capital | +44 (0)20 7408 4090 | |
Nominated Adviser and Broker | ||
Stephane Auton | ||
Edward Mansfield | ||
FTI Consulting | +44 (0)20 3727 1000 | |
Financial Public Relations Advisor | ||
Brett Pollard | ||
Natalie Garland-Collins |
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue‐generating biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.